[HTML][HTML] Identification of MX2 as a novel prognostic biomarker for sunitinib resistance in clear cell renal cell carcinoma
Y Wei, X Chen, X Ren, B Wang, Q Zhang, H Bu… - Frontiers in …, 2021 - frontiersin.org
Background Antiangiogenic agents that specifically target vascular endothelial growth factor
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …
[HTML][HTML] Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
Y Wei, X Chen, X Ren, B Wang, Q Zhang, H Bu… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Background Antiangiogenic agents that specifically target vascular endothelial growth factor
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …
Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
Y Wei, X Chen, X Ren, B Wang… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Antiangiogenic agents that specifically target vascular endothelial growth factor
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …
Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Y Wei, X Chen, X Ren, B Wang, Q Zhang, H Bu… - Frontiers in …, 2021 - europepmc.org
Background Antiangiogenic agents that specifically target vascular endothelial growth factor
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …